20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style24/7 Wall Street • 03/18/26
Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any CrashThe Motley Fool • 03/18/26
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaBusiness Wire • 03/09/26
U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic ArthritisBusiness Wire • 03/07/26
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 03/05/26
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 03/02/26
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure RetirementThe Motley Fool • 03/01/26
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 02/26/26
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast CancerBusiness Wire • 02/26/26
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care ConferenceBusiness Wire • 02/23/26